Patents Assigned to Remedeye Inc.
  • Patent number: 9254289
    Abstract: The present invention discloses methods for treating eye disorders. The methods include the step of administering an effective amount of a topically-administered dipyridamole. Preferably, the topically-administered dipyridamole is formulated as a solution. Preferably, the topically-administered dipyridamole is at least one agent selected from the group consisting of: dipyridamole, and a pharmaceutically-acceptable salt thereof. Preferably, the effective amount corresponds to a concentration of at least about 10?5 molarity. Preferably, the effective amount is based on a treatment administration of at least once every other day.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: February 9, 2016
    Assignee: REMEDEYE INC.
    Inventor: Moshe Rogosnitzky
  • Publication number: 20140275124
    Abstract: The present invention discloses methods for treating eye disorders. The methods include the step of administering an effective amount of a topically-administered dipyridamole. Preferably, the topically-administered dipyridamole is formulated as a solution. Preferably, the topically-administered dipyridamole is at least one agent selected from the group consisting of: dipyridamole, and a pharmaceutically-acceptable salt thereof. Preferably, the effective amount corresponds to a concentration of at least about 10?5 molarity. Preferably, the effective amount is based on a treatment administration of at least once every other day.
    Type: Application
    Filed: March 13, 2013
    Publication date: September 18, 2014
    Applicant: Remedeye Inc.
    Inventor: Moshe Rogosnitzky
  • Publication number: 20140213605
    Abstract: The present invention discloses methods for treating eye disorders using opioid receptor antagonists. The methods include the step of administering an effective amount of a topically-administered opioid receptor antagonist in the absence of moxifloxacin. Preferably, the topically-administered opioid receptor antagonist is formulated as a solution. Preferably, the topically-administered opioid receptor antagonist is at least one agent selected from the group consisting of: naltrexone, naloxone, nalmefene, and a pharmaceutically-acceptable salt thereof. Preferably, the effective amount corresponds to a concentration of at least about 10?7 molarity. Preferably, the effective amount is based on a treatment administration of at least once every other day.
    Type: Application
    Filed: March 11, 2013
    Publication date: July 31, 2014
    Applicant: Remedeye Inc.
    Inventor: Moshe Rogosnitzky